Article
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) - 15 May 1996
Rivoltini L, Loftus D J, Barracchini K, Arienti F, Mazzocchi A, Biddison W E, Salgaller M L, Appella E, Parmiani G, Marincola F M
Abstract excerpt
Cellular immune responses to melanoma-associated Ags are the focus of ongoing studies aimed at developing immunotherapies for treatment of malignant melanoma. Melanoma predominantly affects Caucasians, a population in whom expression of HLA-A2 is prevalent. Among HLA-A2 subtypes, HLA-A*0201 is widely expressed, and HLA-A*0201-restricted, tumor-reactive CTL responses are well studied. We have observed in a group...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
